Pinned Tweet
Arrancamos 2025 con una gran noticia.
Después de muchos meses en las trincheras, ya puedo anunciar que @antaivb y @JME_Ventures serán nuestros socios para lanzar Balance. Queremos ayudar a millones de personas en su lucha contra la obesidad.
findbalance.app/sobre-nosotr…
1
8
669
Jesús Rebollo retweeted
Hay una cosa que me cuesta entender. Somos una micro pyme. Vamos a pagar más de 50K en impuesto de sociedades. ¿Por qué no nos dan la opción de reinvertir ese dinero para hacer un proyecto o contratar a alguien? No pido que nos den una subvención pero sí que podamos reinvertirlo
ya que se está hablando de impuestos, le he pedido a Claude que me haga una infografía sobre el coste empresa de un empleado de 27 años que cobra 70k en Zurich vs 70k en España
en fin... qué puta locura
Jesús Rebollo retweeted
Europe over the last 30 years:
🇪🇪 Estonia: We got rich.
🇵🇱 Poland: We got rich too.
🇮🇪 Ireland: Life is pretty good.
🇩🇪 Germany: Not bad.
🇪🇸 Spain: At least we have sunshine.
🇮🇹 Italy: At least we have pasta.
30 years of economic progress and Spain managed a spectacular 2.76% increase in real wages.
But hey, the tapas are great. 😂
Después de los resultados de PISA en el cole de mi hijo han encontrado una solución.
Han creado un grupo de trabajo que se llama:
Grupo de Trabajo sobre Patios Inclusivos (por lo visto los chavales juegan mucho a deportes con pelota…)
Y tan panchos.
1
2
112
Y las piernas ?
@elmundoes elmundo.es/espana/2026/08/07…
No paran de salir nuevos beneficios derivados de los GLP-1 que van mucho más allá de la pérdida de peso
A new study links GLP-1 drugs and 30-35% reduced incidence of breast cancer, using matched-pair propensity analysis
ascopubs.org/doi/10.1200/OP-…
Confirms other association studies but still no proof
55
Jesús Rebollo retweeted
Miré los muros de la patria mía…
Qué dolor.
How has the Spanish economy performed over the very long run?
To answer, I use Leandro Prados de la Escosura’s (@LdelaEscosura) data on real GDP per capita from 1277 to 2024. I express Spain’s figure as a ratio to Britain’s, since Britain was the first economy to achieve modern economic growth, from around 1660, and has been the leader, or close to it, ever since.
Spain, within its present borders, was prosperous in the Late Middle Ages, well ahead of Britain, then a peripheral corner of Europe. The Black Death and its aftermath hit Spain harder, and by 1360, the two economies had converged.
That parity held until 1600, when Spain began a long decline, in absolute terms (on the eve of the French Revolution, it was barely above its 1600 level, after a deep slump in between) and in relative terms (Britain pulled steadily away). The standard explanations, the Habsburg wars, and the serial bankruptcies run into one problem. They can account for the poor performance between 1550 and 1650, but not for the stagnation between 1650 and 1789. 140 years of stagnation is far more than wars and debt under the Habsburgs can explain.
The series also shows that Spain did not benefit from its empire. That is a problem for every theory tying colonies to modern growth. At most, one can argue that colonies were a necessary condition for takeoff (I do not believe even that, but leave it for another day). One cannot argue that they were sufficient.
The period from 1789 to 1936 was no kinder. The economy grew a little, and Spain built a modern but unfinished liberal state. Yet it never closed the distance to Britain. It is hard not to read the period from 1789 to 1936 as a national failure and the Civil War as its final consequence.
The recent efforts of some historians to paint those years in brighter colors strike me as unfounded. Spain did not fail at modernization as badly as China, but it did not succeed. A deeply corrupt dynasty, closed and incompetent elites in Madrid, Barcelona, and Bilbao, and an economic policy built on intervention and protection (by 1920, Spain was the most protectionist economy in the Western world, so much for the friends of protection) together made the country a basket case.
A cruel civil war left Spain at its historical low, with just 31% of the British GDP per capita. The foreign visitors who arrived in the early 1950s found a poor, backward country.
Policy in the first twenty years of the dictatorship was awful. Autarky was not so much imposed by the Allies as chosen. Spain’s rulers, using their quasi-fascist Weltanschauung, believed growth would come from state intervention, closed markets, and unorthodox fiscal and monetary policy.
Then, in 1959, policy changed. Spain adopted a more orthodox fiscal and monetary policy and opened to foreign investment and trade. The results were spectacular. For forty years, Spain grew briskly and became the modern country it is today. By 2001, it had reached 77% of British GDP per head.
But the internal contradictions of two things eventually became binding: the growth model launched in 1959, and the political regime created by the 1978 constitution. By 2024, Spain had slipped back to 74% of British GDP per head. This is worse than it looks. Britain itself has done poorly over the past twenty years, and losing ground to a weak performer is a bad sign.
Spain stands at a crossroads, economic and political. The country’s foundations no longer work, but its political and business elites have failed to understand this fundamental reality. A good grasp of its economic history helps make sense of its present predicament.
The Self-Help Trap: What 20 Years of “Optimizing” Has Taught Me tim.blog/2026/03/04/the-self…
22
Esta es una de las mejores historias que he visto (si es 100% real)
Estoy convencido que esta industria no está viendo el tsunami que se le viene encima.
A tech consultant in Sydney spent $3,000 and two months to do what Moderna has spent billions trying to scale.
Paul Conyngham adopted Rosie, a staffy-Shar Pei cross, from a shelter in 2019. In 2024, tumors started growing on her back leg. Mast cell cancer, the most common skin cancer in dogs. He tried surgery, chemo, immunotherapy. Nothing shrank the tumors. Just slowed them down while the bills stacked into the tens of thousands.
So he opened ChatGPT and asked it how to cure his dog’s cancer.
The AI didn’t cure anything. What it did was compress months of literature review into hours. It suggested genomic sequencing, walked him through neoantigen identification, helped him build a research pipeline that would normally require a postdoc and a lab budget. He paid $3,000 to sequence Rosie’s tumor DNA at UNSW’s Ramaciotti Centre, then ran the mutations through AlphaFold to model the protein structures. A computational biology professor at UNSW saw his analysis and was, in his own words, gobsmacked that someone with zero biology training had assembled the whole thing.
Then came the part nobody expects. The science was the easy half. Australian ethics approval to run a drug trial on your own pet took three months. Two hours every night after work, filling out a 100-page application. The red tape was harder than designing the vaccine.
Once he cleared that, Páll Thordarson at the UNSW RNA Institute built a custom mRNA vaccine from Conyngham’s data. Sequencing to finished vaccine: less than two months. Conyngham drove 10 hours to deliver Rosie for her first injection in December. One month later, the tennis-ball-sized tumor on her leg had shrunk 75%.
Here’s where the numbers get interesting. Moderna and Merck just reported five-year data on their personalized mRNA cancer vaccine for melanoma. It encodes up to 34 neoantigens per patient. The Phase III trial is fully enrolled. Projected cost per patient: $100,000 to $300,000. Their pipeline is worth an estimated $2.3 billion in annual sales by 2031.
Conyngham did a version of the same workflow for his dog. Sequenced the tumor. Identified the neoantigens. Built a custom mRNA construct. Total cost: $3,000 for sequencing plus university lab time. The gap between those two numbers is where AI is about to rearrange the entire cost structure of precision medicine.
The regulatory moat is real. Conyngham could do this because veterinary experimental treatments face lighter scrutiny than human medicine. There’s no FDA Phase I-III gauntlet for a one-off compassionate use case on a dog. But the technical workflow, tumor sequencing to neoantigen prediction to mRNA synthesis, is converging toward something a motivated person with the right AI tools can orchestrate in weeks instead of years.
One guy, a rescue dog, and a $20/month ChatGPT subscription just produced a proof of concept that the pharmaceutical industry has spent a decade and billions of dollars building toward. The vaccine worked. The tumor shrank. And the only reason it happened is because a dog owner loved his dog enough to spend three months fighting paperwork.
1
78
Jesús Rebollo retweeted
I resigned from OpenAI. I care deeply about the Robotics team and the work we built together. This wasn’t an easy call. AI has an important role in national security. But surveillance of Americans without judicial oversight and lethal autonomy without human authorization are lines that deserved more deliberation than they got. This was about principle, not people. I have deep respect for Sam and the team, and I’m proud of what we built together.
Jesús Rebollo retweeted
The combination of GLP-1 drugs (such as Ozempic) and healthy lifestyle factors was associated with less major adverse cardiovascular events in ~100,000 people with T2D
@TheLancetEndo sciencedirect.com/science/ar…
No pierde el tiempo @sama
I'm joining @OpenAI to bring agents to everyone. @OpenClaw is becoming a foundation: open, independent, and just getting started.🦞
steipete.me/posts/2026/openc…
1
59
He arrancado el día con el último podcast de @joantubau con Leontxo Garcia.
Escuchadlo. Os gustará.
1
30
Estoy buscando a la persona que lidere growth y marketing en Balance
Quien se apunta?
linkedin.com/jobs/view/43586…
























